Loading
Everything in development, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for Small intestine cancer (small bowel adenocarcinoma), drawn from the whole corpus: 1 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
Adjuvant chemotherapy benefit is unproven; BALLAD is the randomised answer.
Second-line therapy for MSS disease is weak; HER2 antibody-drug conjugates and trials in rare GI tumours are the route.
Nothing recorded yet.
Also on OnCo: Find a trial · Expert centres.
Late diagnosis because the small bowel is hard to image; capsule endoscopy and MR enterography surveillance in high-risk groups is being formalised.
Nothing recorded yet.
Nothing recorded yet.
Also on OnCo: Symptoms and red flags · Early detection roadmap.
Rarity fragments research; international registries and platform trials are the response.
Nothing recorded yet.
Also on OnCo: Find a trial · Expert centres.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 8 changes by month →When this page itself was last checked or edited.
Fluoropyrimidine with oxaliplatin (CAPOX or FOLFOX) for six months, extrapolated from colon cancer; BALLAD is the randomised test. (NCCN Category 2A)
A milestone in how this cancer is treated.
A milestone in how this cancer is treated.
Small bowel adenocarcinoma is one of the eligible tumours.
First randomised trial in resected small bowel adenocarcinoma (NCT02502370).